Why the study?
Does rivaroxaban 20 mg once-daily reduce symptomatic recurrent VTE in patients who have completed 6 to 12 months of anticoagulant treatment for acute VTE?
Does rivaroxaban 20 mg once-daily reduce symptomatic recurrent VTE in patients who have completed 6 to 12 months of anticoagulant treatment for acute VTE?
Rivaroxaban 20 mg once-daily significantly reduces the risk of recurrent VTE by 82% compared to placebo in patients who have completed 6-12 months of initial anticoagulation, with a low incidence of major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports extended rivaroxaban use after initial VTE therapy; confirms benefit of prolonged anticoagulation in reducing recurrence.
Harry R. Büller (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: